The health authorities in Saudi Arabia have temporarily suspended imports of a number of drugs produced by the Gulf Pharmaceutical Industries (Julphar).
The Saudi Food and Drug Authority (SFDA) announced the ban which concerns Enoxirt® injection, Narapril® 5mg, Narapril®, Narapril® 20mg, Narapril® 10mg, injection Julmentin®), HA1280 and HA0639.
The regulatory food and drug authority issued directives to withdraw the above-mentioned pharmaceutical products from the market, citing “lack of commitment to the principles of pharmaceutical manufacturing (GMP)”.
SFDA inspectors had visited the firm and reported a number of violators which have an impact on safety of manufactured medication.
The SFDA circular directed to resort to other registered alternative drugs, urging doctors and pharmacists to provide them to patients.
It urged custoemrs to inform the National Center for Medical Alertness and Safety in case of side effects due to the use of drugs on hotline 8002490000; Fax: 00966112057662 or unified number 1999